Approval of the study protocol in South Korea was delayed by approximately four months by inquiries from the local regulatory authorities and recruitment efforts were compromised by a high screen failure rate (58%).

Read how the original recruitment target and timeline were met with more than 1,100 patients screened to yield 420 randomized patients and important data on the efficacy of this investigational vaccine in older, difficult-to-immunize adults.